This review determined the evidence on the use of statins during the peri-operative period to reduce the risk of cardiovascular events. The authors concluded that there was insufficient evidence for routine administration of statins to reduce peri-operative cardiovascular risk. Given the limitations of the evidence base, this conclusion seems reasonable.
scoring system for non-randomised studies. The Jadad scale evaluates the reporting of randomisation, blinding and withdrawals. The checklist for non-randomised studies evaluated reporting, external validity, internal validity (bias and confounding) and power.
Data extraction
Three reviewers independently extracted the data from the included studies; the authors of the primary studies were contacted for additional data where necessary. Intention-to-treat data on death, and/or ACS in the peri-operative period, safety data and the results of multivariate analyses were extracted from each study. Odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were calculated.
Methods of synthesis
How were the studies combined? The studies were combined in separate meta-analyses for RCTs and for other studies, for each primary outcome (perioperative death or ACS event, and peri-operative death), using a random-effects model. ORs and their corresponding 95% CIs were presented.
How were differences between studies investigated?
The studies were grouped by study design and separate analyses for cardiac and non-cardiac surgery were reported. The chi-squared test and I-squared statistic were used to assess statistical heterogeneity.
Results of the review
Eighteen studies were included: 2 RCTs (n=177; 1 non-cardiac surgery and 1 cardiac surgery), 3 prospective noncardiac surgery cohort studies (n=2,886), 12 retrospective cohort studies (n=796,565: 9 non-cardiac surgery and 3 cardiac surgery) and 1 non-cardiac surgery case-control study (n=480).
The RCTs were given Jadad scores of 5 and 2 for quality out of a possible 5. Overall, the 16 non-randomised studies were rated as being of good quality. However, internal validity was only deemed to be fair to moderate; lack of blinding was the main limitation reported.
Peri-operative death or ACS
RCTs (2 trials): the results favoured treatment with statins (OR 0.26, 95% CI: 0.07, 0.99); this was based on 13 events in 177 patients (cardiac and non-cardiac surgery).
Cohort studies (13 studies, n=18,463): significantly fewer incidences of death or ACS were found in the statin group compared with controls (OR 0.70, 95% CI: 0.57, 0.87); no statistical heterogeneity was shown. The results did not differ substantially when only the retrospective trials were considered (OR 0.65, 95% CI: 0.50, 0.84). However, when only the 3 prospective trials were considered, no statistically significant difference between the groups was found (OR 0.91, 95% CI 0.65, 1.27). When grouped by type of surgery, fewer deaths or ACS were found for statin-treated patients, both those undergoing non-cardiac surgery (OR 0.70, 95% CI: 0.53, 0.91) and those undergoing cardiac surgery (OR 0.69, 95% CI: 0.43, 1.11), although this was not statistically significant for cardiac surgery.
Peri-operative death
RCTs: one death occurred in the peri-operative period in the 177 patients randomised.
Cohort studies (n=797,703): 23,498 deaths occurred in the peri-operative period. Overall, significantly fewer perioperative deaths were found in statin users compared with controls (OR 0.58, 95% CI: 0.48, 0.72); no statistical heterogeneity was shown. The results did not differ substantially when broken down by type of surgery (non-cardiac surgery: OR 0.69, 95% CI: 0.65, 0.72; cardiac surgery: OR 0.49, 95% CI: 0.38, 0.64).
Case-control study (n=480): fewer peri-operative deaths were found in the statin group when compared with matched controls (OR 0.22, 95% CI: 0.10, 0.47).
